The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
With a new CEO stepping in to steer the ship, some have wondered whether the move could lead to a slowdown at Vertex. The company's response? We’re still on track—and our pipeline is coming along, too ...
Step aside, Orkambi. Vertex’s new-and-improved cystic fibrosis combo is here. On Monday, the FDA approved Symdeko, a combination of new compound tezacaftor and ivacaftor, a drug already on the market ...
Drug maker Vertex has announced that the FDA has approved tezacaftor/ivacaftor and ivacaftor (Symdeko) for the treatment of the underlying cause of cystic fibrosis (CF) in patients aged 12 or older ...
Agreement also enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once approved in ...
The indication is now for pediatric patients ages six years and older with certain genetic mutations. The US Food and Drug Administration (FDA) has extended the ...
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for ...
US regulators have approved Vertex’ Symdeko, a combination of Kalydeco (ivacaftor) and tezacaftor, to treat certain patients with cystic fibrosis (CF). US regulators have approved Vertex’ Symdeko, a ...
DUBLIN--(BUSINESS WIRE)--The "Symdeko - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Symdeko - Drug Insight, 2019 report provides comprehensive information of the ...
Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has granted approval to Symdeko to treat eligible cystic fibrosis patients as young as six years of age. With the latest approval, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results